SynthesisInternational journal of chronic obstructive pulmonary disease2026
Impact of Emphysema on Therapeutic Efficacy and Immune-Related Pneumonitis Risk in NSCLC Patients Receiving ICIs: A Meta-Analysis of Improved Survival but Increased Toxicity.
Synthesis in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To identify the impact of CT-defined emphysema on efficacy and immune checkpoint inhibitor-related pneumonitis (ICIP) risk among non-small cell lung cancer (NSCLC) patients who receive ICIs. Methods: PubMed, EMBASE, Web of Science and CNKI databases were searched up to January 8, 2025. Primary outcome was the therapeutic efficacy including the progression-free survival (PFS), overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR) and disease control rate (DCR). Second outcome was the ICIP. The hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) were combined. Results: Nine studies with 1076 cases were included. Pooled results demonstrated that the presence of emphysema was significantly associated with improved PFS (HR = 0.43, 95% CI: 0.28-0.67, P < 0.001), OS (HR = 0.43, 95% CI: 0.25-0.75, P = 0.003), PR (OR = 2.10, 95% CI: 1.18-3.75, P = 0.012), PD (OR = 0.60, 95% CI: 0.43-0.83, P = 0.002) and DCR (OR = 1.48, 95% CI: 1.14-1.94, P = 0.004). However, emphysema was associated with increased incidence of ICIP (OR = 1.32, 95% CI: 1.15-1.53, P < 0.001). Conclusion: Based on available evidence, CT-defined emphysema indicates better therapeutic efficacy with longer PFS and OS, but increased risk of ICIP among NSCLC patients receiving ICIs. These findings suggest emphysema may guide personalized immunotherapy decisions in NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.